Ashwani K Singal1, Krishna V R Venkata2, Sarat Jampana3, Fakhar-Ul Islam4, Karl E Anderson5. 1. Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: aksingal@uab.edu. 2. Department of Internal Medicine, The University of Alabama, Montgomery, Alabama. 3. Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas. 4. Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, Birmingham, Alabama. 5. Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas.
Abstract
BACKGROUND: Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. Recently, HCV treatment has improved with direct-acting antivirals (DAA). We review our experience on HCV treatment in patients with PCT with older and newer regimens. MATERIALS AND METHODS: A retrospective chart review was conducted. HCV treatment was attempted 22 times in 13 patients with PCT (5 attempts in 1, 2 in 5 and 1 in the other 7 patients). RESULTS: Before starting HCV treatment, PCT was in complete remission in 16, partial remission in 2, unknown status in 2 and active in 2 instances. PCT relapsed during therapy 6 times (all interferon-based regimens and 2 including telaprevir), 4 requiring treatment interruption. Treatment was interrupted for reasons other than PCT relapse in 2 patients treated with interferon-based regimens. To prevent PCT recurrence, hydroxychloroquine was continued during HCV therapy 6 times (3 interferon regimens, 2 ribavirin regimens without interferon and 1 DAA alone). Twelve patients achieved sustained viral response, 3 with interferon regimens and 9 with DAA. Two patients with active PCT were treated with DAA, with reduction of plasma porphyrins in 1 and normalization in the other at the end of HCV therapy. CONCLUSIONS: HCV treatment regimens including interferon or ribavirin may precipitate PCT relapse. Hydroxychloroquine may be useful to prevent such relapses. In this limited experience, DAA were not associated with PCT relapse. Studies are needed to examine DAA as a primary PCT treatment in HCV-infected patients.
BACKGROUND:Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. Recently, HCV treatment has improved with direct-acting antivirals (DAA). We review our experience on HCV treatment in patients with PCT with older and newer regimens. MATERIALS AND METHODS: A retrospective chart review was conducted. HCV treatment was attempted 22 times in 13 patients with PCT (5 attempts in 1, 2 in 5 and 1 in the other 7 patients). RESULTS: Before starting HCV treatment, PCT was in complete remission in 16, partial remission in 2, unknown status in 2 and active in 2 instances. PCT relapsed during therapy 6 times (all interferon-based regimens and 2 including telaprevir), 4 requiring treatment interruption. Treatment was interrupted for reasons other than PCT relapse in 2 patients treated with interferon-based regimens. To prevent PCT recurrence, hydroxychloroquine was continued during HCV therapy 6 times (3 interferon regimens, 2 ribavirin regimens without interferon and 1 DAA alone). Twelve patients achieved sustained viral response, 3 with interferon regimens and 9 with DAA. Two patients with active PCT were treated with DAA, with reduction of plasma porphyrins in 1 and normalization in the other at the end of HCV therapy. CONCLUSIONS:HCV treatment regimens including interferon or ribavirin may precipitate PCT relapse. Hydroxychloroquine may be useful to prevent such relapses. In this limited experience, DAA were not associated with PCT relapse. Studies are needed to examine DAA as a primary PCT treatment in HCV-infectedpatients.
Authors: Wolfgang Jessner; Manon Der-Petrossian; Lene Christiansen; Harald Maier; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci Journal: Hepatology Date: 2002-11 Impact factor: 17.425
Authors: M I Fiel; T D Schiano; M Guido; S N Thung; K L Lindsay; G L Davis; J H Lewis; L B Seeff; H C Bodenheimer Journal: Am J Clin Pathol Date: 2000-01 Impact factor: 2.493
Authors: Norman G Egger; Douglas E Goeger; Deborah A Payne; Emil P Miskovsky; Steven A Weinman; Karl E Anderson Journal: Dig Dis Sci Date: 2002-02 Impact factor: 3.199
Authors: I Fernández; G Castellano; R E de Salamanca; F Colina; A Gómez de la Cámara; M J Morán; R Muñoz; J A Solís-Herruzo Journal: Scand J Gastroenterol Date: 2003-03 Impact factor: 2.423
Authors: H L Bonkovsky; M Poh-Fitzpatrick; N Pimstone; J Obando; A Di Bisceglie; C Tattrie; K Tortorelli; P LeClair; M G Mercurio; R W Lambrecht Journal: Hepatology Date: 1998-06 Impact factor: 17.425
Authors: Ashwani K Singal; Csilla Kormos-Hallberg; Chul Lee; Vaithamanithi M Sadagoparamanujam; James J Grady; Daniel H Freeman; Karl E Anderson Journal: Clin Gastroenterol Hepatol Date: 2012-09-14 Impact factor: 11.382
Authors: Hashem B El-Serag; Israel C Christie; Amy Puenpatom; Diana Castillo; Fasiha Kanwal; Jennifer R Kramer Journal: Aliment Pharmacol Ther Date: 2019-04-01 Impact factor: 8.171
Authors: Chaudry Nasir Majeed; Christopher D Ma; Ted Xiao; Sean Rudnick; Herbert L Bonkovsky Journal: Drug Des Devel Ther Date: 2022-06-16 Impact factor: 4.319